5931 Darwin Court
Carlsbad, CA 92008
CancerVax Corp.
CancerVax has developed a vaccine comprised of three irradiated melanoma cell lines that appear to be highly immunogenic and appear to cause an immune response in most patients with melanoma.
More from Archive
More from Scrip
• By
Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.
• By
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
• By
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.